Made Scientific recently unveiled its state-of-the-art 60,000ft2 cell therapy GMP manufacturing facility and headquarters in Princeton, NJ, marking a significant milestone in the company’s growth and commitment to advancing cell therapies globally. With a $12 million investment in facility upgrades, equipment, and digital systems, Made Scientific solidifies its standing in the cell therapy sector. The facility’s inauguration was attended by industry leaders, government officials, and community stakeholders, emphasizing the importance of this development for the region.
Syed T. Husain, the chairman and CEO of Made Scientific, highlighted the strategic significance of the new facility in advancing the next generation of cell therapies worldwide. The company’s dedication to long-term manufacturing capacity is evident through this investment, with plans already in motion for a second phase of expansion. The addition of skilled professionals to the workforce will further enhance Made Scientific’s capabilities in meeting the growing demands of the industry while maintaining high-quality standards.
The Princeton facility boasts cutting-edge features, including five ISO 7/Grade B cleanrooms, in-house quality control labs, and specialized process and analytical development capabilities. Leveraging advanced digital infrastructure such as Oracle NetSuite® and Veeva Systems ensures operational efficiency and regulatory compliance throughout the manufacturing process. With a focus on precision, speed, and program visibility, Made Scientific aims to facilitate the seamless translation of innovative cell therapies from clinical development to commercial production.
The recent completion of a 12,000-square-foot expansion of GMP manufacturing cleanroom space further demonstrates Made Scientific’s commitment to meeting regulatory standards and increasing production capacity. This expansion, aligned with FDA and EU Annex 1 compliance requirements, will incorporate high-throughput and automated manufacturing technologies to support late-phase and commercial programs. By adding up to 2,000 additional batches per year, Made Scientific is poised to play a significant role in advancing the accessibility of transformative cell therapies for patients worldwide.
The utilization of cutting-edge technologies such as Autolomous AutoloMATE® for Electronic Batch Records and Manufacturing Execution, along with LabVantage® for Laboratory Information Management, underscores Made Scientific’s commitment to operational excellence and data integrity. These digital solutions enable real-time monitoring, quality control, and seamless integration of manufacturing processes, enhancing overall efficiency and regulatory compliance. By integrating innovative tools into its operations, Made Scientific is well-positioned to lead in the evolving landscape of cell therapy manufacturing.
In conclusion, Made Scientific’s new GMP manufacturing facility in Princeton, NJ, represents a significant advancement in the field of cell therapy manufacturing. With a strong focus on quality, compliance, and operational efficiency, the company is poised to drive innovation and facilitate the translation of groundbreaking therapies from the lab to the clinic. The strategic investments in facility upgrades, skilled workforce expansion, and cutting-edge digital systems underscore Made Scientific’s commitment to shaping the future of cell therapies on a global scale.
Key Takeaways:
– Made Scientific’s new GMP facility in Princeton, NJ, signifies a substantial investment in advancing cell therapy manufacturing capabilities.
– The facility features advanced cleanrooms, quality control labs, and digital infrastructure to ensure regulatory compliance and operational excellence.
– Expansion plans, including the addition of skilled professionals and increased production capacity, highlight Made Scientific’s commitment to long-term growth and innovation in the cell therapy sector.
– By leveraging cutting-edge technologies and a world-class team, Made Scientific aims to support the development and commercialization of transformative cell therapies with precision and efficiency.
Tags: biotech, electronic batch records, quality control, cell therapies, cell therapy, batch records
Read more on genengnews.com